1) Taylor JR, Ryu J, Colby TV, et al. Lymphangio-leiomyomatosis. Clinical course in 32 patients. N Engl J Med. 1990; 323: 1254-60
|
|
|
2) Johnson SR, Tattersfield AE. Lymphangioleiomyo- matosis. Semin Respir Crit Care Med. 2002; 23: 85-92
|
|
|
3) Ryu JH, Moss J, Beck GJ, et al. The NHLBI lymphangioleiomyomatosis registry: character-istics of 230 patients at enrollment. Am J Respir Crit Care Med. 2006; 173: 105-11
|
|
|
4) Taveira-DaSilva AM, Steagall WK, Moss J. Lymph-angioleiomyomatosis. Cancer Control. 2006; 13: 276-85
|
|
|
5) Sandrini A, Krishnan A, Yates DH. S-LAM in a man: the first case report. Am J Respir Crit Care Med. 2008; 177: 356; author reply 357
|
|
|
6) Burger CD. S-LAM in men: is pulmonary function different from that seen in women? Am J Respir Crit Care Med. 2008; 177: 356; author reply 357
|
|
|
7) Schiavina M, Di Scioscio V, Contini P, et al. Pulmonary lymphangioleiomyomatosis in a karyotypically normal man without tuberous sclerosis complex. Am J Respir Crit Care Med. 2007; 176: 96-8
|
|
|
8) McCormack FX, Moss J. S-LAM in a man? Am J Respir Crit Care Med. 2007; 176: 3-5
|
|
|
9) Kim NR, Chung MP, Park CK, et al. Pulmonary lymphangioleiomyomatosis and multiple hepatic angiomyolipomas in a man. Pathol Int. 2003; 53: 231-5
|
|
|
10) The European Chromosome 16 Tuberous Sclero-sis Consortium. Identification and chara-cterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993; 75: 1305-15
|
|
|
11) van Slegtenhorst M, de Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997; 277: 805-8
|
|
|
12) Smolarek TA, Wessner LL, McCormack FX, et al. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet. 1998; 62: 810-5
|
|
|
13) Yu J, Astrinidis A, Henske EP. Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis. Am J Respir Crit Care Med. 2001; 164: 1537-40
|
|
|
14) Kumasaka T, Seyama K, Mitani K, et al. Lymph-angiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangio- leiomyomatosis. Am J Surg Pathol. 2004; 28: 1007-16
|
|
|
15) Kumasaka T, Seyama K, Mitani K, et al. Lymph-angiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am J Surg Pathol. 2005; 29: 1356-66
|
|
|
16) Seyama K, Kumasaka T, Souma S, et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol. 2006; 4: 143-52
|
|
|
17) Young LR, Inoue Y, McCormack FX. Diagnostic potential of serum VEGF-D for lymphangioleio-myomatosis. N Engl J Med. 2008; 358: 199-200
|
|
|
18) Pea M, Martignoni G, Zamboni G, et al. Peri-vascular epithelioid cell. Am J Surg Pathol. 1996; 20: 1149-53
|
|
|
19) Juvet SC, McCormack FX, Kwiatkowski DJ, et al. Molecular pathogenesis of lymphangioleiomyo-matosis: lessons learned from orphans. Am J Respir Cell Mol Biol. 2007; 36: 398-408
|
|
|
20) Arbiser JL, Brat D, Hunter S, et al. Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms. J Am Acad Dermatol. 2002; 46: 376-80
|
|
|
21) El-Hashemite N, Walker V, Zhang H, et al. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res. 2003; 63: 5173-7
|
|
|
22) Huber S, Bruns CJ, Schmid G, et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int. 2007; 71: 771-7
|
|
|
23) Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008; 358: 140-51
|
|
|
24) Davies DM, Johnson SR, Tattersfield AE, et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med. 2008; 358: 200-3
|
|
|
25) Glasgow CG, Taveira-Dasilva AM, Darling TN, et al. Lymphatic involvement in lymphangioleio-myomatosis. Ann NY Acad Sci. 2008; 1131: 206-14
|
|
|
26) Mitani K, Kumasaka T, Takemura H, et al. Cytologic, Immunocytochemical and Ultra-structural Characterization of Lymphangioleiomyo-matosis cell clusters in chylous effusions of patients with lymphangioleomyomatosis. Acta Cytologica. 2009; 53: 402-9
|
|
|
27) Sugimoto R, Nakao A, Yamane M, et al. Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation. J Heart Lung Transplant. 2008; 27: 921-4
|
|
|
28) Chen F, Bando T, Fukuse T, et al. Recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation. Transplant Proc. 2006; 38: 3151-3
|
|
|
29) Karbowniczek M, Astrinidis A, Balsara BR, et al. Recurrent lymphangiomyomatosis after trans-plantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med. 2003; 167: 976-82
|
|
|
30) Bittmann I, Rolf B, Amann G, et al. Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis. Hum Pathol. 2003; 34: 95-8
|
|
|
31) Bittmann I, Dose TB, Muller C, et al. Lymphangio-leiomyomatosis: recurrence after single lung transplantation. Hum Pathol. 1997; 28: 1420-3
|
|
|
32) O'Brien JD, Lium JH, Parosa JF, et al. Lymph-angiomyomatosis recurrence in the allograft after single-lung transplantation. Am J Respir Crit Care Med. 1995; 151: 2033-6
|
|
|
33) Crooks DM, Pacheco-Rodriguez G, DeCastro RM, et al. Molecular and genetic analysis of dissemi-nated neoplastic cells in lymphangioleiomyo-matosis. Proc Natl Acad Sci U S A. 2004; 101: 17462-7
|
|
|
34) Henske EP. Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosomes Cancer. 2003; 38: 376-81
|
|
|
35) Issaka RB, Oommen S, Gupta SK, et al. Vascular endothelial growth factors-C and D induces proliferation of lymphangioleiomyomatosis cells through autocrine crosstalk with endothelium. Am J Pathol. 2009 e-pub
|
|
|